High rate of clinical recurrence in @entity1 with XXXX treated with early high-dose corticosteroids.

@entity1 @entity1667 @entity697 @entity82 @entity231 @entity229 @entity941 @entity7375 @entity1533 @entity288
PURPOSE: To analyse the rate of clinical recurrences in Brazilian @entity1 with @entity7375 after early high-dose corticosteroid treatment. METHODS: Retrospective study including @entity1 treated with early high-dose @entity288 ( @entity229 , 1-1.5  mg/kg/day, or 3-day 1  g @entity1667 pulsetherapy) within 1  month from disease onset followed by slow taper (at least 6  months). @entity1 with a minimum 12-month follow-up were subdivided based on the presence of disease recurrence or persistence after 6  months from initial presentation into: @entity697 ( @entity697 , no recurrences), chronic-recurrent (CR), and chronic-recurrent with @entity82 ( @entity82 ). Recurrences were defined as the presence of clinical and/or @entity941 angiography findings. RESULTS: Twenty-nine @entity1 (58 eyes) with a median follow-up of 65  months were included. Six (21  %), 11 (38  %) and 12 (41  %) @entity1 were allocated to @entity697 , CR, and @entity82 groups respectively. Though having received treatment within 1  month of onset, median time to initial treatment differed among groups (11, 15, and 25  days, in @entity697 , CR, and @entity82 groups respectively). Intensity of immunosuppression, @entity231 development, and longer time to achieve logMAR visual acuity  <=0.8 differed significantly among the groups, being more severe in @entity82 group. @entity1533 *0405 allele followed the same trend, though not reaching significance (0.5 in @entity697 group, 0.6 in CR, and 0.8 in @entity82 ). CONCLUSION: VKH disease in Brazilian @entity1 evolved to chronic-recurrent disease in 79  % of cases; 38  % developed @entity82 , in spite of similar initial treatment regimens. Time to initiate treatment influenced outcomes.
